A fixed-dose combination (FDC) of an Angiotensin II Receptor Blocker (ARB) and an Angiotensin-Converting Enzyme (ACE) inhibitor. This dual renin-angiotensin-aldosterone system (RAAS) blockade provides synergistic antihypertensive and cardioprotective effects, offering superior blood pressure control and target organ protection compared to monotherapy in many patients, particularly those with high cardiovascular risk or proteinuric chronic kidney disease.
Adult: One tablet (Valsartan 80mg + Ramipril 5mg) once daily. Initiation: Should only be initiated in patients already stabilized on the individual components at these doses or titrated upwards from lower doses. Not for initial therapy.
Note: Can be taken with or without food, but consistency is key (preferably without food for more consistent valsartan absorption). Swallow whole with a glass of water. Dose timing is usually morning to avoid nocturnal diuresis. Monitor BP 2-6 hours after first dose for hypotension.
Provides dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS). Ramipril inhibits the Angiotensin-Converting Enzyme (ACE), reducing the conversion of Angiotensin I to the potent vasoconstrictor Angiotensin II and decreasing the breakdown of bradykinin (a vasodilator). Valsartan selectively blocks the AT1 receptor, through which Angiotensin II exerts its effects (vasoconstriction, aldosterone release, sodium retention, cardiac remodeling). This dual action leads to more complete suppression of RAAS, resulting in vasodilation, reduced aldosterone secretion (decreasing sodium/water retention and potassium excretion), and decreased sympathetic outflow.
Pregnancy: CATEGORY D (2nd & 3rd trimester), CATEGORY C (1st trimester). Contraindicated. Use can cause fetal injury and death, including oligohydramnios, fetal renal failure, skull hypoplasia, and pulmonary hypoplasia. Discontinue immediately if pregnancy is detected.
Driving: May cause dizziness, lightheadedness, or fatigue, especially during initiation. Patients should be cautioned about operating machinery or driving until they know how the medication affects them.
| Diuretics (especially Potassium-sparing: Spironolactone, Eplerenone, Amiloride) | Profoundly increased risk of hyperkalemia and hypotension, particularly after first dose. | High |
| NSAIDs (e.g., Ibuprofen, Diclofenac, Naproxen) | Reduced antihypertensive effect, increased risk of acute renal impairment and hyperkalemia. | High |
| Lithium | Increased serum lithium levels and toxicity due to reduced renal clearance. | High |
| Aliskiren | Increased risk of hyperkalemia, hypotension, and renal impairment, especially in diabetes/renal disease. | High (Contraindicated in specific populations) |
| Other Antihypertensives (Beta-blockers, CCBs, Alpha-blockers) | Additive hypotensive effect. | Moderate |
| Potassium Supplements / Salt Substitutes (high in K+) | Increased risk of hyperkalemia. | Moderate |
| Antidiabetics (Insulin, Sulfonylureas) | Ramipril may potentiate hypoglycemic effect. | Moderate |
| Gold injections (Sodium aurothiomalate) | Increased risk of nitritoid reactions (flushing, nausea, hypotension) with Ramipril. | Moderate |
| Allopurinol, Immunosuppressants, Procainamide | Increased risk of hypersensitivity reactions including Stevens-Johnson syndrome with Ramipril. | Moderate |